Ungated Post | 06 Mar 2020

Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing

The processes required for C&GT manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.

Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.


Read the full report


Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:

Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.

To find out more about our capabilities, contact:

EMEA
Paul Donnelly
020 3910 8000
Email

Americas
Jeffrey Klonoski
+1 646 503 3048
Email

Asia
Christie Tang
+852 3974 8841
Email

Related Services

Post

Investment behaviour in sustainable finance

To meet the 2050 climate targets, the global sustainability and climate goals will require massive public and private investments of more than 131 trillion euros.

Find Out More

Post

Investitionsverhalten bei nachhaltigen Finanzinstrumenten

Investitionsverhalten bei nachhaltigen Finanzinstrumenten: Eine verhaltensökonomisch experimentelle Analyse von "ESG-Präferenzen" und deren Implikationen für Finanzinstitutionen und Politik.

Find Out More

Post

Tobacco Track & Trace Systems Across Africa

The purpose of this study is to review progress towards implementing track & trace (T&T) systems across the continent, to assess the compliance of existing systems with ITP requirements and to investigate the potential benefits from a regional perspective to combating illicit trade.

Find Out More